Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has initiated the human trial of ARO-ALK7, a novel RNA interference (RNAi) ...

Arrowhead Pharmaceuticals, Inc.'s deal with Sarepta expands its pipeline, but limited plozasiran market and competition ...

Here are the latest stock rating downgrades by Seeking Alpha analysts: Palantir (NASDAQ:PLTR). Hold to sell by Bay Area Ideas ...

Arrowhead Pharmaceuticals Inc (ARWR) reports robust earnings, strategic partnerships, and pipeline progress, while navigating regulatory and market uncertainties. On a per-share basis, the ...

On the charts, Arrowhead Pharmaceuticals (NASDAQ: ARWR) showed a “double top,” touching around $20 twice between September and October, before crashing down more than 30% in the last week.

Investors in Arrowhead Pharmaceuticals Inc (Symbol: ARWR) saw new options begin trading this week, for the October 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the pricing of an underwritten registered offering of 15,790,000 shares of its common stock ...

Investors in Arrowhead Pharmaceuticals Inc (Symbol: ARWR) saw new options begin trading this week, for the September 20th expiration. One of the key inputs that goes into the price an option buyer ...

The stock price of Arrowhead (NASDAQ: ARWR), a biopharmaceutical company that develops RNA interference therapies, has seen a large 30% fall over the last five trading days. The decline came after ...

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s product pipeline includes Plozasiran, which has completed Phase 3 ...